Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma

The optimal number of brentuximab vedotin cycles in the treatment of systemic anaplastic large‐cell lymphoma (sALCL) prior to autologous stem‐cell transplantation (ASCT) is unknown. This case illustrates the possible benefit of prolonged brentuximab vedotin before ASCT in sALCL and may help clinical...

Descripción completa

Detalles Bibliográficos
Autor principal: Koh, Youngil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930222/
https://www.ncbi.nlm.nih.gov/pubmed/29744059
http://dx.doi.org/10.1002/ccr3.1461
_version_ 1783319464919433216
author Koh, Youngil
author_facet Koh, Youngil
author_sort Koh, Youngil
collection PubMed
description The optimal number of brentuximab vedotin cycles in the treatment of systemic anaplastic large‐cell lymphoma (sALCL) prior to autologous stem‐cell transplantation (ASCT) is unknown. This case illustrates the possible benefit of prolonged brentuximab vedotin before ASCT in sALCL and may help clinical decision‐making, especially in chemorefractory disease.
format Online
Article
Text
id pubmed-5930222
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59302222018-05-09 Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma Koh, Youngil Clin Case Rep Case Reports The optimal number of brentuximab vedotin cycles in the treatment of systemic anaplastic large‐cell lymphoma (sALCL) prior to autologous stem‐cell transplantation (ASCT) is unknown. This case illustrates the possible benefit of prolonged brentuximab vedotin before ASCT in sALCL and may help clinical decision‐making, especially in chemorefractory disease. John Wiley and Sons Inc. 2018-03-08 /pmc/articles/PMC5930222/ /pubmed/29744059 http://dx.doi.org/10.1002/ccr3.1461 Text en © 2018 The Author. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Koh, Youngil
Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma
title Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma
title_full Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma
title_fullStr Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma
title_full_unstemmed Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma
title_short Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma
title_sort extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930222/
https://www.ncbi.nlm.nih.gov/pubmed/29744059
http://dx.doi.org/10.1002/ccr3.1461
work_keys_str_mv AT kohyoungil extendeduseofbrentuximabvedotinbeforeautologousstemcelltransplantationwouldbenefitrefractorysystemicanaplasticlargecelllymphoma

Ejemplares similares